Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 16/20 | 0.54 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15900580 | 1.00 | IDH1 (0.54) | IDH1LIMK2PANK3PIK3CDPIK3R1 | |
| SCHEMBL15900579 | 1.00 | IDH1 (0.54) | IDH1LIMK2PANK3PIK3CDPIK3R1 | |
| SCHEMBL15900665 | 0.89 | IDH1 (0.63) | IDH1 | |
| SCHEMBL15900664 | 0.89 | IDH1 (0.63) | IDH1 | |
| SCHEMBL14251970 | 0.89 | IDH1 (0.42) | IDH1 | |
| SCHEMBL15900845 | 0.87 | IDH1 (0.57) | IDH1PIK3CDPIK3R1 | |
| SCHEMBL15900843 | 0.87 | IDH1 (0.57) | IDH1PIK3CDPIK3R1 | |
| SCHEMBL15900507 | 0.86 | IDH1 (0.66) | IDH1 | |
| SCHEMBL15900545 | 0.86 | IDH1 (0.59) | IDH1PANK3 | |
| SCHEMBL15900916 | 0.83 | IDH1 (0.54) | IDH1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856279-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-11 | — | — | US | disclosed |
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213580-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | RNASE1, TP53, MCL1 | IDH1 414/4885LIMK2 1550/4885PANK3 2695/4885 |
| US-20160229876-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | MCL1, TP53, MMP8 | IDH1 469/4885LIMK2 1497/4885PANK3 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.